Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions.

Bertaux C, Daelemans D, Meertens L, Cormier EG, Reinus JF, Peumans WJ, Van Damme EJ, Igarashi Y, Oki T, Schols D, Dragic T, Balzarini J.

Virology. 2007 Sep 15;366(1):40-50. Epub 2007 May 11.

2.

L-SIGN (CD209L) isoforms differently mediate trans-infection of hepatoma cells by hepatitis C virus pseudoparticles.

Falkowska E, Durso RJ, Gardner JP, Cormier EG, Arrigale RA, Ogawa RN, Donovan GP, Maddon PJ, Olson WC, Dragic T.

J Gen Virol. 2006 Sep;87(Pt 9):2571-6.

PMID:
16894195
3.

L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus.

Cormier EG, Durso RJ, Tsamis F, Boussemart L, Manix C, Olson WC, Gardner JP, Dragic T.

Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14067-72. Epub 2004 Sep 15.

4.

CD81 is an entry coreceptor for hepatitis C virus.

Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T.

Proc Natl Acad Sci U S A. 2004 May 11;101(19):7270-4. Epub 2004 May 3.

5.
7.

CCR5 and CXCR4 usage by non-clade B human immunodeficiency virus type 1 primary isolates.

Thompson DA, Cormier EG, Dragic T.

J Virol. 2002 Mar;76(6):3059-64.

8.
9.

Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120.

Cormier EG, Persuh M, Thompson DA, Lin SW, Sakmar TP, Olson WC, Dragic T.

Proc Natl Acad Sci U S A. 2000 May 23;97(11):5762-7.

10.

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, Moore JP.

Proc Natl Acad Sci U S A. 2000 May 9;97(10):5639-44.

Supplemental Content

Loading ...
Support Center